Capecitabine
|
|
Generic/Working Name
|
Capecitabine |
Trade Name
|
Xeloda |
Company Name
|
Roche |
Drug Type
|
Fluoropyrimidine with antineoplastic activity |
Drug Class
|
Antimetabolite |
Dose
|
1,000 milligrams (mg) per squared meter (m2) |
Route
|
Oral (p.o.) |
Schedule of Administration
|
Capecitabine was administered at 1,000 mg/m2 by mouth twice daily. The dose of capecitabine was calculated with a maximum body surface area (BSA) of 2.0 m2 for patient safety. Capecitabine dose was adjusted if BSA changed >5% from baseline. |
Sorafenib
|
|
Generic/Working Name
|
Sorafenib |
Trade Name
|
Nexavar |
Company Name
|
Bayer and Onyx Pharmaceutics |
Drug Type
|
Small molecule |
Drug Class
|
Tyrosine kinase inhibitor |
Dose
|
200 milligrams |
Route
|
Oral (p.o.) |
Schedule of Administration
|
Sorafenib was administered at 200 mg by mouth twice daily. Dose was increased to 400 mg by mouth each morning and 200 mg by mouth each evening (dose level + 1) for cycle 2, and then to 400 mg by mouth twice daily (dose level + 2) for cycle 3 and onward, assuming no attributable AEs during the prior cycle. |